

CLAIMS

[Claim 1]

A crystal of (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one, the crystal exhibiting an X-ray powder diffraction spectrum containing at least three characteristic peaks at diffraction angles ($2\theta \pm 0.2^\circ$) selected from 9.5° , 14.3° , 16.7° , 19.1° , 20.8° , 21.9° , and 25.2° .

[Claim 2]

The crystal according to claim 1, which exhibits an X-ray powder diffraction spectrum containing at least five characteristic peaks at diffraction angles ($2\theta \pm 0.2^\circ$) selected from 9.5° , 14.3° , 16.7° , 19.1° , 20.8° , 21.9° , and 25.2° .

[Claim 3]

The crystal according to claim 1 or 2, which exhibits an X-ray powder diffraction spectrum containing characteristic peaks at diffraction angles ($2\theta \pm 0.2^\circ$) of 9.5° , 14.3° , 16.7° , 19.1° , 20.8° , 21.9° , and 25.2° .

[Claim 4]

The crystal according to any one of claims 1 to 3, which has a chemical purity of 99.0% or more.

[Claim 5]

The crystal according to any one of claims 1 to 4, which exhibits an endothermic peak (the highest peak value) in the vicinity of 166°C in differential scanning calorimetry measurement.

[Claim 6]

A pharmaceutical composition comprising the crystal according to any one of claims 1 to 5.

[Claim 7]

A pharmaceutical composition for oral administration, the composition comprising the crystal according to any one of claims 1 to 5.